Opinion: Star Trek Medicine

An apology for basic research

Written byDean Tantin
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

DEVIANTANT, BALSAVORWhen I was growing up, I didn’t want to become a physician. Unlike the best medical students, I never had a fire in the belly for seeing and treating patients. Instead, I wanted to find out how things work, and to apply what I learned to discover new things. And so I became a scientist. Along with life, love and music, science has been a chief motivating force ever since. I know I share an enjoyment of the scientific process—and a fondness for those moments of discovery—with many researchers, and that therefore my story will likely sound familiar.

But there is something else that always drove me, and I suspect many of us, toward science. Until a few years ago I couldn’t easily put my finger on it. What that something else turns out to be provides, I believe, our strongest possible argument for robust support of basic scientific research—in particular, the kind of high risk/high reward science that seems in danger of falling out of fashion these days.

In most instances, the enjoyment academic scientists derive from conducting research is enough to counter the negatives, such as the unrelenting vagaries and vicissitudes of the grant-funding process. In the United States, budget pressures and resource constrictions have placed increased stress on the system. For example, the constant biomedical dollars available at the US ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies